Lipocine (LPCN) Cash & Current Investments (2011 - 2025)

Lipocine (LPCN) has 15 years of Cash & Current Investments data on file, last reported at $23.9 million in Q4 2025.

• Quarterly Cash & Current Investments fell 35.4% year-over-year to $23.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $23.9 million (down 35.4% YoY) and the FY2025 annual result came in at $23.9 million, down 35.4% from the prior year.
• Cash & Current Investments slipped to $23.9 million in Q4 2025, from $26.3 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $87.4 million in Q4 2021 to a low of $23.9 million in Q4 2025.
• A 5-year average of $50.9 million and a median of $45.7 million in 2021 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2021 — Cash & Current Investments surged 345.38% — and 2023, when it slumped 36.18%.
• Tracing LPCN's Cash & Current Investments over 5 years: stood at $87.4 million in 2021, then dropped by 29.72% to $61.5 million in 2022, then tumbled by 36.18% to $39.2 million in 2023, then retreated by 5.64% to $37.0 million in 2024, then tumbled by 35.4% to $23.9 million in 2025.
• The last three Cash & Current Investments figures came in at $23.9 million (Q4 2025), $26.3 million (Q3 2025), and $29.5 million (Q2 2025), per Business Quant data.